Marshall Wace LLP Boosts Stock Holdings in Haemonetics Co. (NYSE:HAE)

Marshall Wace LLP boosted its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 25.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 279,997 shares of the medical instruments supplier's stock after acquiring an additional 57,116 shares during the period. Marshall Wace LLP owned 0.56% of Haemonetics worth $21,862,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Stifel Financial Corp grew its holdings in shares of Haemonetics by 87.5% during the third quarter. Stifel Financial Corp now owns 13,770 shares of the medical instruments supplier's stock worth $1,107,000 after purchasing an additional 6,425 shares in the last quarter. Nordea Investment Management AB raised its position in shares of Haemonetics by 5.5% during the 4th quarter. Nordea Investment Management AB now owns 104,175 shares of the medical instruments supplier's stock valued at $8,152,000 after buying an additional 5,385 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Haemonetics during the 4th quarter worth $402,000. KBC Group NV lifted its holdings in shares of Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 712 shares during the last quarter. Finally, Pacer Advisors Inc. grew its position in Haemonetics by 36.1% in the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock worth $789,000 after acquiring an additional 2,680 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on HAE shares. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and dropped their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Needham & Company LLC reduced their price target on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. JMP Securities lowered their price objective on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a report on Friday, February 7th. Raymond James reaffirmed a "strong-buy" rating and set a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Finally, Barrington Research cut their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Haemonetics presently has an average rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Trading Up 0.2 %

NYSE:HAE traded up $0.15 during mid-day trading on Friday, reaching $62.07. 68,277 shares of the company's stock traded hands, compared to its average volume of 893,789. Haemonetics Co. has a 12-month low of $55.30 and a 12-month high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a 50 day moving average price of $62.86 and a 200-day moving average price of $72.25. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of 24.44, a PEG ratio of 1.11 and a beta of 0.41.

Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, sell-side analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.